GYNECOLOGIC CANCERS

Patients with relapsed, platinum-sensitive <em>BRCA</em>-mutant ovarian cancer experienced a 13.6-month improvement in progression-free survival (PFS) with the PARP inhibitor olaparib versus placebo, according to data reported at the Society of Gynecologic Oncology meeting.

Patients with <em>BRCA</em>-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 Society of Gynecologic Oncology Annual Meeting.

Ursula A. Matulonis, MD, discusses results of the phase III NOVA trial showed the PARP inhibitor niraparib demonstrated an improvement in PFS versus placebo as a maintenance therapy for patients with high-grade serous ovarian cancer.

Mismatch repair&ndash;deficient endometrial cancers exhibited significantly higher levels of PD-L1 expression compared with MMR-intact tumors.

Ursula A. Matulonis, MD, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.

Intensity-modulated radiation therapy has been associated with less acute and chronic gastrointestinal toxicity, compared with standard pelvic radiation in the treatment of patients with cervical or endometrial cancer, according to results of a phase III study.

Dmitriy Zamarin, MD, PhD, discusses&nbsp;the next steps necessary to advance immunotherapy in the field of gynecologic cancers.

Alon Altman, MD, discusses a study that examined the effects of number of neoadjuvant chemotherapy cycles on patient outcomes.

Results of a recent phase III trial suggested that the PARP inhibitor niraparib warrants consideration for patients with recurrent, platinum-sensitive, high-grade ovarian cancer, irrespective of <em>BRCA</em> status, a reviewer of the study concluded.

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

Patients with ovarian cancer who were treated at the highest volume centers had superior overall survival but also higher readmission rates compared with lower volume hospitals, casting doubt on the value of this measure for patients with cancer.

Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against the human papillomavirus.

During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD,&nbsp;offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing.&nbsp;

Patients with relapsed, platinum-sensitive, high-grade, ovarian cancer saw activity with the PARP inhibitor rucaparib, according to findings from the ARIEL2 study presented at the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland.&nbsp;

Hypermethylation of 2 wild-type tumor-associated genes increased ovarian cancer responsiveness to the PARP inhibitor rucaparib, according to a subgroup analysis of the randomized ARIEL2 trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting on Women&rsquo;s Cancer.

<p>Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer. Neoadjuvant chemotherapy has been shown to decrease surgical morbidity, lowering the complication rates and risk of death.&nbsp;</p>

A new analysis of a randomized phase II trial showed PARP inhibitor rucaparib slowed progression of relapsed <em>BRCA</em>-mutant ovarian cancer regardless of whether the mutations were somatic or germline.

According to a recent study, lack of clinical coverage and time off topped the perceived hindrances to gynecologic oncologists&rsquo; participation in global health activities.

The results of a new study have provided yet more evidence that survivors of endometrial cancer should be closely monitored for cardiovascular disease.

The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin has been granted a priority review designation&nbsp;by the FDA for the treatment of patients with relapsed or refractory ALL.

The much anticipated initial results of the Gynecologic Oncology Group 252 trial failed to provide additional clarity for the use of intravenous versus intraperitoneal chemotherapy in patients with ovarian cancer.

The number of futile laparotomies was reduced with diagnostic laparoscopy in patients with suspected advanced-stage ovarian cancer, according to the results of a recent study.

Douglas A. Levine, MD, discusses the relationship between <em>EMSY</em> and <em>BRCA</em>, the potential to target <em>EMSY</em> amplified tumors with PARP inhibitors, and the future of ovarian cancer treatment.

A full regulatory approval is being sought for blinatumomab as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor ALL.